Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG) in ...

Samsung Biologics achieved record annual revenue of 4.55 trillion won in 2024, with a 23 percent increase year over year.

Samsung Bioepis collaborates with Teva to launch Epysylli in U.S. market Samsung Bioepis and Teva join forces to introduce a ...

Samsung Bioepis and Teva have entered into a license, development and commercialization agreement for Epysqli ...

Samsung Biologics has made history by becoming the nation's first biotech company to hit 4 trillion won ($2.78 billion) in ...

Samsung Bioepis' Q1 2025 report shows oncology, ophthalmology, and pegfilgrastim biosimilars have gained significant market share, while immunology, filgrastim, epoetin alfa, and insulin glargine ...

INCHEON, South Korea, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today released its First Quarter 2025 Biosimilar Market Report, marking the eighth edition of the Quarterly Biosimilar ...

Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar ...

New partnerships aim to expand Teva’s biosimilar portfolio and enhance access to high-cost biologics across key markets.

South Korean biosimilars developer Samsung Bioepis and Israel’s Teva Pharmaceutical Industries have entered into a license, development and commercialization agreement for Epysqli (eculizumab-aagh), ...

INCHEON, Korea and TEL AVIV, Israel, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced today that the companies ...

Pharmaceutical Industries announced that the companies have entered into a license, development and commercialization agreement for EPYSQLI, Samsung Bioepis’ biosimilar to Soliris in the United States ...